Dutasteride for the treatment of benign prostatic hyperplasia

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1399-1408

  Wu, Christopher ^a   Kapoor, Anil ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

5 reductase inhibitor; Benign prostatic hyperplasia; Dutasteride; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ANDROSTANOLONE; DOXAZOSIN; DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; FINASTERIDE; PLACEBO; TAMSULOSIN; TESTOSTERONE;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EAR NOSE THROAT DISEASE; EJACULATION DISORDER; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER RESPIRATORY TRACT INFECTION;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; AZASTEROIDS; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 84878827885     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.797965     Document Type: Article

References (35)

1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005;7(Suppl 9):S3-S14
2. Girman CJ. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol 1998;82(Suppl 1):34-43
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-9
4. Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 2011;107(7):1110-16
5. Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60(5):1105-13
6. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172(4 Pt 1):1399-403
7. Wright AS, Thomas LN, Douglas RC, et al. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996;98(11):2558-63
8. Rittmaster RS. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008;22(2):389-402
9. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19(6):413-25
10. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006;290(5):E952-60
11. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61
12. Iehle C, Radvanyi F, Gil Diez de Medina S, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68(5-6):189-95
13. Thomas LN, Douglas RC, Vessey JP, et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170(5):2019-25
14. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57(2):134-9
15. Imperato-McGinley J, Gautier T, Zirinsky K, et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1992;75(4):1022-6
16. Sinnecker GH, Hiort O, Dibbelt L, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 1996;63(1):223-30
17. Merck & Co. I. PROSCAR- (finasteride) tablets 5 mg: summary of prescribing information. Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, USA; 2011. [Cited 13 February 2013]
18. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group. N Engl J Med 1998;338(9):557-63
19. Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem 2006;6(5):405-21
20. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
21. GlaxoSmithKline. Avodart (dutasteride) soft gelatin capsules 0.5 mg: summary of full prescribing information. GlaxoSmithKline; Research Triangle Park, NC; 2012. [Cited 10 February 2013]
22. Frye SV, Haffner CD, Maloney PR, et al. Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent. J Med Chem 1995;38(14):2621-7
23. Tian G, Mook RA Jr, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995;34(41):13453-9
24. Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282(3):1496-502
25. Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10(2):149-54
26. Evans HC, Goa KL. Dutasteride. Drugs Aging 2003;20(12):905,16; discussion 917-8
27. Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282(3):1496-502
28. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41
29. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46(4):488,94; discussion 495
30. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-31
31. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44(4):461-6
32. Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the enlarged prostate international comparator study (EPICS). BJU Int 2011;108(3):388-94
33. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective european doxazosin and combination therapy (PREDICT) trial. Urology 2003;61(1):119-26
34. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362(13):1192-202
35. Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365(2):97-9